Paul A. Ainsworth, a director in Sterne Kessler’s Trial & Appellate Practice Group, is a first-chair trial attorney with a practice focused on patent and trade secret disputes in federal district courts, at the U.S. International Trade Commission (ITC), and before the U.S. Court of Appeals for the Federal Circuit. Paul’s clients include established and emerging leaders in the pharmaceutical, biopharmaceutical, medical devices, chemical manufacturing, and consumer products industries.

Paul has been a leader in the firm’s award-winning Hatch-Waxman litigation practice nearly since its inception. For more than two decades, Paul has represented innovators and generic drug clients in patent litigation. Companies in the pharmaceutical industry understand that the intersection of intellectual property and regulatory exclusivity are critical to their success, and they hire Paul for their most important matters due to his experience and acumen in this area.

Paul is also a leader in the firm’s high-profile ITC practice. Section 337 investigations have a well-earned reputation for being fast-paced, high stakes, and unforgiving. Paul has a proven record of successfully representing complainants and respondents in investigations involving their most important product markets. He is also experienced representing and counseling companies in enforcement activities following the issuance of an exclusion order, including proceedings before the Intellectual Property Rights Branch of the U.S. Customs & Border Patrol.

Further, Paul has significant experience counseling and representing clients in trade secret matters, including under the Federal Defend Trade Secrets Act.  With uncertainty growing around the ability of U.S. patent law to protect IP portfolios, start-up and established businesses turn to Paul for planning and executing effective trade secret strategies to safeguard what is often their most valuable asset. And when clients are faced with allegations of misuse, he has a proven record of delivering results for his clients.

Paul is a contributing author of Patent Office Litigation, Second Edition, published in 2017 by Thomson Reuters Westlaw. The book provides a comprehensive exploration of patent office litigation proceedings, including how the proceedings interact with other aspects of patent procurement and enforcement, while delivering practical analysis and advice. He is also a contributing author of Pre-ANDA Litigation: Strategies and Tactics for Developing a Drug Product and Patent Portfolio, Third Edition, published in 2022 by the American Bar Association and ANDA Litigation: Strategies and Tactics for Pharmaceutical Patent Litigators, Third Edition, published in 2019 by the American Bar Association.

Paul began his legal career as a law clerk for the Honorable Sue L. Robinson, United States District Judge, District of Delaware. In addition to his patent litigation practice, he has also represented leading civil rights organizations on state and federal civil rights issues. In 2011, the National LGBT Bar Association named Paul as one of the “Best LGBT Lawyers Under 40” in recognition of both his accomplishments as an IP litigator and his contributions to the advancement of LGBT civil rights.

When not in the courtroom, Paul is most likely to be found hiking in the Allegheny Mountains with his dog, Rugby.

Hatch-Waxman and Biosimilar Matters

  • Nexus Pharmaceuticals, Inc. v. Somerset Therapeutics (D.N.J.) (lead counsel for Somerset in litigation concerning ephedrine sulfate injections—Emerphed®)
  • Catalyst Pharmaceuticals and SERB SA v. Hetero Pharmaceuticals; Catalyst Pharmaceuticals and SERB SA v. Lupin Ltd. (D.N.J) (counsel for Catalyst and SERB in litigation concerning amifampridine—Firdapse®)
  • Catalyst Pharmaceuticals v. MSN Labs (D.N.J) (counsel for Catalyst and SERB in litigation concerning perampanel—Fycompa®)
  • Catalyst Pharmaceuticals and SERB SA v. Jacobus Pharmaceuticals (D.N.J) (counsel for Catalyst and SERB in litigation concerning amifampridine—Firdapse®)
  • Genentech, Inc. et al. v. Sandoz, Inc. et al (D.N.J.) (counsel for Sandoz in litigation concerning rituximab)
  • Braintree Laboratories v. Lannett Co. (D. Del.) (lead counsel for Lannett Co. in litigation concerning a bowel prep kit—Suprep®.)
  • Adapt Pharma Ops.  v. Teva Pharmaceuticals USA (D.N.J.) (counsel for Teva in litigation concerning a treatment for opioid overdose—Narcan®)
  • Insys Therapeutics v. Teva Pharmaceuticals USA (D. Del.) (counsel for Teva in litigation concerning a pain management treatment–Subsys®)
  • AstraZeneca AB et al. v. Kremers Urban Pharmaceuticals Inc., (D.N.J.) (lead counsel for Kremers Urban in litigation concerning a treatment for gastroesophageal reflux disease–Nexium®)
  • Salix Pharmaceuticals, Inc. v. Novel Laboratories, Inc., (D. Del.) (counsel for Novel Laboratories in litigation concerning a treatment for ulcerative colitis—Apriso®)
  • IntelGenx Corp. v. Wockhardt Bio, AG, (D.N.J.) (lead counsel for IntelGenx in litigation concerning a treatment for major depression—Forfivo®)
  • Helsinn Healthcare S.A. v. Aurobindo Pharma Ltd., (D. Del.) (lead counsel for Aurobindo in litigation concerning an anti-nausea medication—Aloxi®)
  • Alcon Pharmaceuticals Ltd. v. Apotex, Inc., (D. Del.) (counsel for Apotex in litigation concerning a treatment for bacterial conjunctivitis–Vigamox®)
  • Galderma Laboratories Inc. et al v. Amneal Pharmaceuticals, LLC et al., (D. Del.) (counsel for Amneal in litigation concerning a treatment for rosacea–Oracea®)
  • Medeva Pharma Suisse A.G. et al v. Roxane Laboratories, Inc., (D.N.J.); Medeva Pharma Suisse A.G. et al. v. Par Pharmaceuticals et al. (D.N.J.) (counsel for patentee and licensee in a multi-case litigation concerning a treatment for ulcerative colitis–Asacol®)
  • Shire LLC v. Watson Laboratories, Inc., (S.D.N.Y)(S.D. Fla.) (counsel for patentee litigation concerning a treatment for attention deficit hyperactivity disorder – Adderall XR®)

ITC

  • In re Certain High-Performance Gravity-Fed Water Filters and Products Containing the Same, 337-TA-1294 (lead counsel for Complainant Brita in an ITC Investigation pertaining to pour-through water filters)
  • In re Certain Electronic Nicotine Delivery Systems and Components Thereof, 337-TA-1139 (counsel for Complainant Juul Labs, Inc. in an ITC Investigation pertaining to electronic nicotine delivery systems)
  • In re Certain Electronic Nicotine Delivery Systems and Components Thereof, 337-TA-1141 (counsel for Complainant Juul Labs, Inc. in an ITC Investigation pertaining to electronic nicotine delivery systems)
  • In re Certain Road Construction Machines and Components Thereof, ITC Investigation No. 337-TA-1088 (counsel for Respondents Wirtgen GmbH, Wirtgen America, and Joseph Vögele AG in an ITC investigation pertaining to road construction equipment)
  • In re Certain Road Milling Machines and Components Thereof, ITC Investigation No. 337-TA-1067 (counsel for Complainant Wirtgen American in an ITC investigation pertaining to road construction equipment)
  • In re Lithium Silicate Materials and Products Containing the Same, ITC Investigation No. 337-TA-911 (counsel for Complainant Ivoclar Vivadent AG in an ITC investigation pertaining to lithium silicate-based dental prostheses)
  • In re Certain Motorized Self-Balancing Vehicles, ITC Investigation No. 337-TA-1000 (counsel for Respondent Powerboard in an ITC investigation pertaining to personal transport vehicles)
  • In re Certain Overflow and Drain Assemblies for Bathtubs and Components Thereof, ITC Investigation No. 337-TA-993 (counsel for Complainant WCM Industries in an ITC investigation pertaining to screwless bathtub drain assemblies)
  • In re Certain Video Game Machines and Related Three-Dimensional Pointing Devices, ITC Investigation No 337-TA-658 (counsel for respondent Nintendo in an ITC investigation concerning television interactive program guide and 3D pointing device technologies)

Trade Secrets

  • Pharmazam, LLC v. Thermo Fisher Scientific, Inc. (M.D. Fla.) – Represented Thermo Fisher Scientific in an allegations relating to trade secret misappropriation. Plaintiff voluntarily dismissed complaint after Sterne Kessler filed a motion to dismiss for failure to state a claim.
  • Sonatype, Inc. Takari, Inc. (D. Md.) – Filed a complaint alleging that the company’s founder misappropriated, copied, and wrongfully disclosed Sonatype’s intellectual property and trade secrets after separating from the company. Sterne Kessler achieved a favorable settlement shortly after filing the complaint.
  • Confidential matter. Represented a pharmaceutical company in a trade secret dispute related to the misappropriation of trade secret information involving a former business development partner. Former development partner used confidential business information in an effort to extort a license to certain intellectual property. Conducted an internal investigation that led to evidence of misappropriation. Negotiated a favorable resolution for our client.
  • Confidential matter. Represented a biotechnology client in a dispute with a former founder and chief scientific officer. Conducted an internal investigation that led to evidence of breaches of the former founder’s employment and separation agreements.  Negotiated a favorable resolution for our client.

Other

  • Wirtgen America v. Caterpillar (Del.) (counsel for Wirtgen America in litigation concerning road milling machines)
  • University of California v. Broad Institute (PTAB) (counsel for The Regents of the University of California, University of Vienna, and Emmanuelle Charpentier in an interference proceeding relating to CRISPR technology)
  • Julbo, Inc. v. Oakley, Inc. (N.D. Cal.) (lead counsel for Oakley in litigation concerning goggles)
  • The Kingsford Charcoal Co. v. Creative Spark (PTAB) (counsel for petitioner in proceeding challenging the patentability of a patent pertaining to charcoal briquets)
  • KAZ USA, Inc. v. Brita LP, (PTAB) (counsel for patent owner in proceeding challenging the patentability of a patent pertaining to water filters)
  • 1-800-CONTACTS, d/b/a/ glasses.com v. DITTO Technologies, Inc. (D. Utah) (lead counsel for plaintiff glasses.com in litigation relating to systems for virtual display and modeling of eyewear)
  • Naraka Intellectual Property LLC v. Atlassian, Inc. (M.D. Pa.) (lead counsel for defendant in litigation relating to videoconferencing systems)
  • Ivoclar AG v. Glidewell Laboratories, (D. N.J.) (counsel for Ivoclar in litigation pertaining to lithium-silicate dental prostheses)
  • Intellectual Ventures v. Ericsson (Fed. Cir.) (appellate counsel for patent owner in appeal from an inter partes review relating to wireless communications systems)
  • Butamax Advanced Biofuels LLC v. Gevo, Inc., (PTAB) (counsel for petitioner in proceeding challenging the patentability of certain biofuel manufacturing patents)
  • Automated Tracking Solutions, LLC v. Awarepoint Corp., (E.D. Va.); Automated Tracking Solutions, LLC v. Teletracking Technologies, Inc. et al. (E.D. Va.) (counsel for patentee in multi-case litigation relating to radio frequency identification (RFID) technology)

  • Best Lawyers, “The Best Lawyers in America®” (2025 – 2023)
  • World Intellectual Property Review (WIPR), “WIPR Leaders” (2024 – 2023)
  • Super Lawyers, “Super Lawyer – Washington, DC” (2021 – 2017)
  • Super Lawyers, “Rising Star – Washington, DC” (2014)

  • J.D., William & Mary Law School
  • B.A., Political Science, The George Washington University

  • District of Columbia
  • Maryland
  • West Virginia
  • U.S. District Court for the District of Maryland
  • U.S. District Court for the District of Columbia
  • U.S. District Court for the Eastern District of Michigan
  • U.S. District Court for the Southern District of West Virginia
  • U.S. Court of Appeals for the Federal Circuit

  • U.S. District Court for the District of Delaware

Webinar

The ITC Advantage: Securing Exclusionary Relief for Patented Features

Virtual, October 17, 2024 1:00 PM - 2:00 PM EDT

Speaking Engagement

2024 LSX Nordic Congress

Copenhagen, Denmark, Bella Center, October 8, 2024 1:50 PM - 2:40 PM EDT

Speaking Engagement

W&M@Work Boston: Innovation in Health & Technology Panel and Breakfast

Cambridge, MA, Catalyst Restaurant, September 18, 2024 8:00 AM - 10:30 AM EST

Webinar

Navigating Trade Secrets Under the FTC’s Non-Compete Ban

Virtual, June 12, 2024 1:00 PM - 2:00 PM EDT

Webinar

ITC Section 337 Year in Review

Virtual, February 28, 2024 2:00 PM - 3:00 PM EST

Webinar

Trade Secrets at the ITC

Virtual, November 15, 2023 1:00 PM - 2:00 PM EST

Speaking Engagement

Meat & Potatoes Episode 224: Paul A. Ainsworth, Sterne Kessler

Virtual, September 13, 2023

Webinar

Minimizing Your Risk of Being Sued Before the USITC

July 19, 2023 1:00 PM - 2:00 PM EST

Speaking Engagement

Mitigating Risks and Attracting Rewards – How To Capitalize and Spot Innovation

London, UK, Business Design Centre, May 4, 2023 11:10 AM - 12:00 PM EST

Speaking Engagement

2023 Focus on Pharma

Washington, DC, April 14, 2023 8:30 AM - 6:00 PM EST

Webinar

Drug Development Pathway Series: Intellectual Property Workshop

Virtual, October 28, 2020 4:00 PM - 5:00 PM EST

Webinar

Secondary Considerations: Latest Guideposts

July 30, 2020 2:00 PM - 3:00 PM EST

Speaking Engagement

International IP Skills Summit (IIPSS)

Hyderabad, India, Hyatt Place Hyderabad, February 26, 2020 12:00 AM - 11:59 PM EST

Speaking Engagement

Summit on Biosimilars

New York, NY, New York Marriott East Side Hotel, June 24, 2019 1:30 PM - 2:30 PM EST

Speaking Engagement

The Sedona Conference’s Patent Conference: Promoting Invention, Entrepreneurship, Economic Growth, and Job Creation

Washington, DC, Covington & Burling LLP, January 17, 2019

Speaking Engagement

Clinical Innovation: Fair and Effective Incentives for New Uses of Established Drugs

Washington, DC, February 8, 2018 8:30 AM - 5:30 PM EST

Global TEC Forum

October 6, 2016

Related News & Insights

From Paul A. Ainsworth

Client Alert

August 27, 2024

Update: FTC’s Ban on Non-Compete Agreements Set Aside

Paul A. Ainsworth, Jonathan Tuminaro, Ph.D.

In the News

July 31, 2024

Trade Secrets Cases To Watch in 2024: A Midyear Report

Law360

Firm News

July 8, 2024

Five Sterne Kessler Attorneys Honored as 2024 WIPR Leaders by World Intellectual Property Review

Sterne, Kessler, Goldstein & Fox

Client Alert

July 8, 2024

Update Regarding FTC’s Ban on Non-Compete Agreements

Paul A. Ainsworth, Jonathan Tuminaro, Ph.D.

Articles

July 5, 2024

Amazon’s Patent Evaluation Express (APEX) Program Has Declaratory Judgment Action Risks for Patent Owners

The Patent Lawyer Joseph H. Kim, Paul A. Ainsworth

Articles

May 15, 2024

ITC Ruling Has Serious IP Implications For Foreign Imports

Law360 Paul A. Ainsworth, Cristen A. Corry

In the News

May 10, 2024

Patent Owners Face Risks In Amazon Program After Ruling

Law360

Client Alert

May 8, 2024

FTC Issues Final Rule Banning (Almost All) Non-Compete Agreements

Jonathan Tuminaro, Ph.D., Paul A. Ainsworth

Articles

May 6, 2024

Amazon’s Patent Evaluation Express (APEX) Program Has Declaratory Judgment Action Risks for Patent Owners

Sterne, Kessler, Goldstein & Fox Joseph H. Kim, Paul A. Ainsworth

In the News

March 18, 2024

Brita Brings ITC Filter Patent Row To Federal Circuit

Law360

In the News

February 28, 2024

Jury Awards Wirtgen $12.9M Against Caterpillar in Milling Machine Lawsuit

Equipment World

Firm News

February 27, 2024

Sterne Kessler and Patterson IP Law Team Up to Secure $12.9M Wirtgen Win Over Caterpillar

Sterne, Kessler, Goldstein & Fox

In the News

February 27, 2024

Caterpillar Owes Deere $13 Million in Road-Milling Patent Trial

Bloomberg Law

In the News

February 26, 2024

Caterpillar to Pay Wirtgen $12.9M in Damages After Patent Battle

Construction Briefing

Articles

February 14, 2024

The Public Interest Impact – Considerations from AliveCor and Masimo

Sterne, Kessler, Goldstein & Fox Davin Guinn, Paul A. Ainsworth

Reports

February 14, 2024

2023 ITC Section 337 Year in Review: Analysis & Trends

Sterne, Kessler, Goldstein & Fox Multiple Authors

Firm News

February 14, 2024

Sterne Kessler Publishes 2023 ITC Section 337 Year in Review: Analysis & Trends Report

Sterne, Kessler, Goldstein & Fox

In the News

February 28, 2023

Brita Lands Win at ITC Against Water Filter Rivals

Law360

Articles

November 16, 2022

Trade Secrets in the United States

IAM Paul A. Ainsworth, Ryan E. Conkin

In the News

September 12, 2022

Korean Co. Can't Be First To Invent CRISPR, PTAB Told

Law360

Firm News

September 9, 2022

Sterne Kessler Wins Hatch-Waxman Impact Case of the Year Award at 2022 LMG Life Sciences Americas Awards

Sterne, Kessler, Goldstein & Fox

Firm News

August 8, 2022

Sterne Kessler Raises Over $34,000 for the Legal Aid Society of the District of Columbia

Sterne, Kessler, Goldstein & Fox

Firm News

July 14, 2022

Sterne Kessler Client Catalyst Pharmaceuticals, Inc. Reaches Patent Litigation Settlement

Sterne, Kessler, Goldstein & Fox

In the News

May 6, 2022

Fed. Circ. Rejects Narcan Maker's Redo Bid In Patent Suit

Law360

In the News

February 18, 2022

Litigator of the Week Runners-Up and Shout Outs

Law.com

In the News

February 11, 2022

Federal Circuit Tosses Naloxone Patents

Law Street Media

In the News

February 10, 2022

Teva Win Invalidating Narcan Patents Upheld by Federal Circuit

Bloomberg Law

In the News

February 10, 2022

Court Affirms Teva Win in Fight Over Generic Narcan Anti-Overdose Drug

Reuters

In the News

February 10, 2022

Split Fed. Circ. Won't Restore 4 Narcan Patents

Law360

In the News

March 25, 2021

How 2020 ANDA Litigation Played Out – And What to Expect for 2021

Managing IP

In the News

March 15, 2021

Federal Circuit Backs Caterpillar Rival's Patent Win

Law360

In the News

December 18, 2020

Fed. Circ. Agrees That Caterpillar ITC Patent Claim Is Invalid

Law360

Firm News

October 8, 2020

Sterne Kessler Client Wins 2020 Nobel Prize in Chemistry for CRISPR-Cas9 Technology

Sterne, Kessler, Goldstein & Fox P.L.L.C.

In the News

June 23, 2020

Obviousness Doomed Narcan Patents After NJ Bench Trial

Law360

In the News

June 5, 2020

Teva Invalidates Opiant Patents In Narcan Suit

Law360

Firm News

April 30, 2020

Sterne, Kessler, Goldstein & Fox Attorneys Named 2020 Super Lawyers and Rising Stars

Sterne, Kessler, Goldstein & Fox P.L.L.C.

Articles

February 26, 2020

Fed. Circ. Amgen Biosimilar Ruling Raises IP Damages Risk

Law360 Paul A. Ainsworth

In the News

July 23, 2019

Caterpillar Hit With Import Ban In Latest Round Of ITC Battle

Law360

Articles

May 16, 2019

Proposed BPCIA reforms: More music, same dance

Managing Intellectual Property Paul A. Ainsworth, Lauren A. Watt

In the News

April 22, 2019

Caterpillar Can't Ax Road Milling Machine Patent At ITC

Law360

In the News

March 8, 2019

Senate Patent Bill To Boost Biosimilars Needs Work, Attys Say

Law360

In the News

December 3, 2018

Zimmer, Stryker Set to Fight Over Huge Damages Award

Bloomberg Law

Articles

August 25, 2017

Strategy Considerations for Biosimilar Applicants after Sandoz v. Amgen

Bloomberg BNA Multiple Authors

Articles

July 28, 2017

Licensing Considerations After Impression Products v. Lexmark

Bloomberg BNA Michael Q. Lee, Paul A. Ainsworth

Articles

July 17, 2017

You Can Dance If You Want To

Sterne, Kessler, Goldstein & Fox Multiple Authors

Client Alert

June 12, 2017

The Patent Dance is Optional

Multiple Authors

In the News

June 6, 2017

Appealing PTAB Loss, IV Finds Tough Crowd at Fed. Circ.

Law360

Client Alert

May 30, 2017

The Supreme Court Redefines Patent Exhaustion

Michael Q. Lee, Paul A. Ainsworth

In the News

May 23, 2017

High Court’s Venue Ruling Limits Where Generic Drugmakers Can Be Sued

Bloomberg BNA

Books and Chapters

February 17, 2017

Patent Office Litigation - Second Edition 2017

Thomson Reuters Westlaw Multiple Authors

Articles

December 16, 2016

Ten Takeaways From the FDA's December 2016 Revisions to its Hatch-Waxman Regulations

Bloomberg BNA's Patent, Trademark & Copyright Journal Paul A. Ainsworth, Chandrika Vira

Client Alert

May 13, 2016

Defend Trade Secrets Act of 2016 Client Advisory

Paul A. Ainsworth

Articles

April 14, 2016

Trade Secret Pitfalls For The Hatch-Waxman Litigant

Law360 Paul A. Ainsworth

Articles

April 8, 2016

Acorda Therapeutics v. Mylan Pharmaceuticals: A New Kind of Jurisdiction for ANDA Cases

Bloomberg BNA Pharmaceutical Law & Industry Report Paul A. Ainsworth

In the News

February 16, 2016

Fed. Circ. Backs PTAB Ax Of Gevo Jet Fuel Patent

Law360

Articles

July 27, 2015

Trade Secret Claim Strategies: ITC Vs. DTSA

Law360 Paul A. Ainsworth

Articles

March 6, 2015

The Daimler Confusion And Its Impact On ANDA Litigation

Law360 Paul A. Ainsworth

In the News

April 8, 2014

Hospira Can't Get Helsinn Aloxi Suit Dismissed

Bloomberg BNA Pharmaceutical Law & Industry Report